Present regulation and public policy mandate the safety and efficacy of pharmaceuticals. Patients and advocacy groups evaluate benefits in a more relative and subjective manner. These value systems may not coincide with regulatory and market judgments. Strict liability biases drug development toward the establishment of safety, sometimes to the detriment of efficacy. Special avenues may be required to maintain access to very efficacious compounds with marginal safety profiles.
